Executive Summary
- Decision: do not initiate, increase or agent-select a position size. If a human-approved, mandate-compliant position already exists, maintain at most that unchanged exposure. Reported growth and operating cash flow justify continued observation, but the evidence does not establish durable product-level economics, acquisition-cohort returns, executed pro forma financing or downside liquidity. [claim.valeant.cutoff.revenue-engine; claim.valeant.cutoff.gaap-base; judgment.valeant.cutoff.maintain-bounded-exposure]
- Strongest case for increasing: Valeant reported FY2014 revenue of USD 8,263.5 million, operating income of USD 2,039.7 million and operating cash flow of USD 2,294.7 million; management also forecast more than USD 500 million of Salix savings and more than 20% Cash EPS accretion in 2016. The first set is reported GAAP evidence; the second remains a company forecast. [table.valeant.cutoff.gaap-operating-base; claim.valeant.cutoff.salix-synergy-accretion]
- Why that is insufficient: the issuer-attributed acquisition increment represented 91.4191% of the change in reported revenue, interest expense represented 42.3149% of operating cash flow, and goodwill plus net intangibles represented 78.1782% of assets. These are descriptive scale checks—not organic-growth attribution, interest coverage or impairment forecasts. [table.valeant.cutoff.deterministic-checks; model-run.valeant.cutoff-descriptive-checks]
- Abstention: do not calculate intrinsic value, a target price, price attractiveness or position size. Verified capitalization, product and cohort cash flows, executed debt, downside liquidity, mandate and risk-budget inputs are incomplete. [claim.valeant.cutoff.valuation-abstention; judgment.valeant.cutoff.valuation-abstention]
This learner packet is outcome-blind. It admits only evidence public by 2015-02-25T23:59:59Z and asks for the exposure decision at 2015-02-26T14:30:00Z. It does not infer later events from missing cutoff evidence.
Decision frame
The committee cannot undo Valeant's already-signed Salix agreement. Its live alternatives are to increase exposure now, leave at most a human-approved mandate-compliant existing position unchanged, or reduce or avoid exposure. The recommendation authorizes no initiation, increase, agent-selected size or external action; it buys future information while preserving explicit kill rules. [claim.valeant.cutoff.salix-signed-commitment; judgment.valeant.cutoff.maintain-bounded-exposure]
The evidence base combines Valeant's FY2014 10-K, a filed investor presentation, the filed Salix transaction documents and joint release, and contemporaneous Reuters reporting. Issuer strategy, synergy, Cash EPS and deleveraging statements are labeled as claims; reported GAAP line items and signed terms are kept separate. source · valeant.cutoff.2014-10k source · valeant.cutoff.business-model-425 source · valeant.cutoff.salix-8k source · valeant.cutoff.salix-release source · valeant.cutoff.reuters-salix
What is established at the cutoff
Valeant reported revenue increasing from USD 5,769.6 million in FY2013 to USD 8,263.5 million in FY2014. Its bridge attributed USD 2,279.9 million of incremental product-sales revenue to 2013 and 2014 acquisitions and USD 670.7 million to the remainder of the existing business after named adjustments. The deterministic 43.2248% reported-growth calculation is valid, but the 91.4191% acquisition-increment ratio is not a standardized organic-growth share or causal attribution. [table.valeant.cutoff.revenue-engine; table.valeant.cutoff.deterministic-checks; evidence.valeant.cutoff.revenue-bridge]
At December 31, 2014, cash was USD 322.6 million and current plus noncurrent long-term debt was USD 15,254.6 million. Goodwill of USD 9,346.4 million and net intangibles of USD 11,255.9 million sat within USD 26,353.0 million of assets. The filing also disclosed leverage and interest-coverage covenants and material impairment sensitivity. [table.valeant.cutoff.capital-base; claim.valeant.cutoff.asset-intensity-risk; claim.valeant.cutoff.leverage-capacity]
The signed Salix terms specified USD 158 cash per share without a financing condition. One disclosed conditional financing path included up to USD 5,550 million of incremental term loans and USD 9,600 million of unsecured bridge commitments. Commitments are neither executed draws nor available liquidity. [table.valeant.cutoff.salix-terms; evidence.valeant.cutoff.salix-deal-terms; evidence.valeant.cutoff.salix-financing-commitments]
Six underwriting gates
1. Product necessity, switching and the decision unit
Valeant described a decentralized portfolio of durable products, organic growth, output-focused R&D, cash generation and short-payback acquisitions. That narrative does not reveal which patient, prescriber, payer and channel decision unit produces durable cash, what alternatives exist, or why users continue to choose each product. [claim.valeant.cutoff.strategy-model; evidence.valeant.cutoff.strategy]
The gate is a product-by-channel ledger reconciling units, net price, mix, access, prescriber retention, inventory, returns, required investment and after-tax cash contribution. No exposure increase is justified while a material residual is unexplained. [claim.valeant.cutoff.product-governance-gap; judgment.valeant.cutoff.product-governance-gate; table.valeant.cutoff.decision-unknowns]
2. Organic commercial engine
The favorable view points to reported growth and an issuer claim of roughly 7% pro forma organic growth. The skeptical view points to the large acquisition-attributed revenue increment and the absence of a standardized price-volume-mix bridge. Both can be true; neither establishes durable organic cash growth at the decision unit. [claim.valeant.cutoff.strategy-model; claim.valeant.cutoff.revenue-engine; conflict.valeant.cutoff.strategy-versus-lineage]
The gate is a bridge from GAAP revenue and operating cash flow to acquisitions, disposals, price, units, mix, foreign exchange, retention, inventory and required investment. It must tie without a material unexplained residual and remain positive under approved downside assumptions. [assumption.valeant.cutoff.organic-durability; table.valeant.cutoff.decision-unknowns]
3. Acquisition diligence, integration and reinvestment
Valeant forecast more than USD 500 million of annual Salix savings within six months, mainly from corporate overhead and R&D rationalization, and more than 20% Cash EPS accretion in 2016. It also disclosed that Salix had reported five to nine months of wholesaler inventory for its top four products and forecast a greater-than-USD-500-million 2015 revenue effect from working that inventory down. Forecast savings and known inventory risk therefore belong in the same integration test. [claim.valeant.cutoff.salix-synergy-accretion; claim.valeant.cutoff.salix-inventory-risk; conflict.valeant.cutoff.salix-synergy-versus-risk]
The gate is an acquisition-cohort schedule reconciling purchase price, purchase accounting, one-time integration cost, realized recurring savings, R&D and commercial reinvestment, inventory sell-through, returns and after-tax cash return. Savings that depend on breaching product continuity, access, quality or approved R&D milestones fail the gate. [assumption.valeant.cutoff.integration-execution; table.valeant.cutoff.decision-unknowns]
4. GAAP, adjusted earnings and earnings-to-cash
The cutoff record establishes FY2014 GAAP revenue of USD 8,263.5 million, operating income of USD 2,039.7 million, R&D expense of USD 246.0 million, finite-lived-intangible amortization and impairment of USD 1,550.7 million, interest expense of USD 971.0 million and operating cash flow of USD 2,294.7 million. [table.valeant.cutoff.gaap-operating-base; evidence.valeant.cutoff.gaap-income; evidence.valeant.cutoff.gaap-cash-flow]
It does not provide a governed bridge from Cash EPS, pro forma organic growth or claimed acquisition IRRs to GAAP earnings, debt service, integration cost and cohort cash return. Nor does a 2.9769% R&D-to-revenue ratio establish adequate reinvestment. The gate requires stable definitions, purchase accounting, tax, working capital, share count and internal-control evidence before any adjusted metric enters the decision. [claim.valeant.cutoff.gaap-nongaap-gap; assumption.valeant.cutoff.accounting-governance; table.valeant.cutoff.deterministic-checks]
5. Debt, interest, liquidity and covenants
The cutoff balance sheet carried USD 15,254.6 million of current and noncurrent long-term debt against USD 322.6 million of cash. Cash was 2.1148% of that debt, and FY2014 interest expense was 42.3149% of operating cash flow. Neither ratio is a liquidity or coverage calculation. [claim.valeant.cutoff.leverage-capacity; table.valeant.cutoff.deterministic-checks]
The no-financing-condition agreement and conditional commitment facilities make executed terms—not headline commitment size—the gate. Treasury must supply pro forma sources and uses, rates, maturities, collateral, covenants, hedges, minimum cash and stressed operating cash flow. Reduce before further commitment if approved cash or covenant-headroom buffers are breached, or re-underwrite after two consecutive misses against the disclosed deleveraging path. [claim.valeant.cutoff.salix-signed-commitment; assumption.valeant.cutoff.financing-deleveraging; table.valeant.cutoff.decision-unknowns]
6. Governance, customer harm, regulatory exposure and valuation readiness
The packet does not establish misconduct, customer harm, regulatory action or future impairment. It does establish that product access, complaints, channel exceptions, regulatory correspondence, internal controls and board remediation are missing from the underwriting record. Missing decision-critical evidence lowers readiness; it does not become a negative fact. [claim.valeant.cutoff.product-governance-gap; judgment.valeant.cutoff.product-governance-gate]
Governance evidence must be independently tested before an increase. A material unresolved customer-harm, regulatory, revenue-recognition, inventory or board-control conflict is a reduce-or-avoid trigger. Valuation remains a separate gate and is blocked until capitalization, cash-flow, financing, mandate and risk inputs are complete and human approved. [judgment.valeant.cutoff.valuation-abstention; claim.valeant.cutoff.valuation-abstention]
Alternatives and scenario frame
| Alternative | Cutoff support | Principal objection |
|---|---|---|
| Increase now | Strong reported growth and operating cash flow; management's strategy, synergy and accretion claims | Product and cohort economics, adjusted bridges, financing and downside liquidity are unresolved |
| No initiation or increase | Leaves at most a human-approved mandate-compliant existing position unchanged while awaiting evidence | Any retained exposure still bears signed-deal, leverage, integration and governance risk |
| Reduce or avoid | Asset intensity, leverage, inventory and evidence gaps make downside difficult to bound | Reported operations and cash generation provide material opposing evidence |
The outcome-blind scenario weights are 30% for integration and organic gates clearing, 45% for mixed execution with slower deleveraging, and 25% for operating, accounting or financing impairment. They are subjective branches, not calibrated base rates, expected returns or valuation probabilities. Every branch uses the same non-authoritative deterministic descriptive model; none produces a target price. [assumption.valeant.cutoff.scenario-weights; model-run.valeant.cutoff-descriptive-checks]
Recommendation, monitoring and kill rules
Do not initiate, increase or agent-select a position size. If a human-approved mandate-compliant position already exists, maintain at most that unchanged exposure with moderate confidence until all six gates have documentary lineage and a deterministic, human-approved valuation demonstrates an approved margin of safety. [judgment.valeant.cutoff.maintain-bounded-exposure; judgment.valeant.cutoff.valuation-abstention]
Monitor six operational records:
- Product-by-channel net economics and customer access, quarterly and before acquisitions.
- A GAAP-tied organic revenue and cash-flow bridge, quarterly.
- Acquisition-cohort integration, reinvestment and after-tax return, monthly during integration and quarterly thereafter.
- GAAP-to-adjusted and earnings-to-cash reconciliations, at every filing and before any adjusted metric is used.
- Executed debt, minimum cash and covenant headroom, monthly and at financing events.
- Customer, regulatory and board-control exceptions, monthly with immediate escalation of material events.
The immediate kill rules are a material unresolved revenue-recognition or internal-control exception, breached approved downside-liquidity or covenant buffers, integration savings that violate product continuity or quality gates, or a material unresolved customer-harm or regulatory conflict. Two consecutive material integration or deleveraging schedule misses force re-underwriting.
Further questions before committing capital
- Which products and channels generate positive after-tax cash after rebates, returns, inventory normalization and required commercial and R&D investment?
- Can price, units, mix, acquisition, disposal, foreign exchange and retention effects reconcile exactly to GAAP revenue and operating cash flow?
- What acquisition-cohort cash returns emerge after purchase accounting, integration costs, taxes, working capital and reinvestment?
- What did Salix's audited sell-through, returns and revenue-recognition control evidence show at the cutoff?
- What debt instruments would actually be issued, with what rates, maturities, collateral, covenants, hedges and stressed liquidity?
- What customer-access, complaint, regulatory and board-control evidence would falsify the favorable thesis?
- What verified capitalization, forecast, mandate and risk budget would permit a deterministic valuation and approved position size?
Caveats
The calculation run is deterministic and source-lined but non-authoritative because no frozen model-registry execution receipt exists. The USD 14.5 billion Salix enterprise-value figure is contemporaneous reporting, not an independent reconstruction; dividing it by Valeant's FY2014 operating cash flow yields only a cross-period scale check. [claim.valeant.cutoff.independent-context; model-run.valeant.cutoff-descriptive-checks]
The packet preserves facts, company claims, assumptions, unresolved conflicts and analyst judgments as different epistemic types. It cannot infer an outcome, wrongdoing or security return from later knowledge or from evidence absent at the cutoff.